GleamWall
中文EN

DRMA Dermata Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1853816 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-7.4%
TTM EPS YoY-121.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-241.5%
ROA-162.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets41.1%
Debt / equity0.00x
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-10.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$2.93M$8.20M
SG&A expense$4.84M$4.31M
Operating income-$7.77M-$12.51M
Income tax—$0
Net income-$7.56M-$12.29M
EPS (basic)-8.16-80.32
EPS (diluted)-8.16-80.32
Weighted avg. shares (diluted)926,192152,974
Balance sheet
Cash & equivalents$7.52M$3.16M
Current assets$7.86M—
Total assets$7.86M$3.53M
Total liabilities$1.64M$1.97M
Shareholders' equity$6.22M$1.56M
Shares outstanding2.66M251,725
Cash flow statement
Operating cash flow-$7.76M-$11.16M
Financing cash flow$12.12M$6.89M
Stock-based compensation$143,732$657,649

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.